Summary & Overview
CPT 80372: Tapentadol Drug Assay
CPT code 80372 identifies a laboratory drug assay to detect or quantify tapentadol, a centrally acting opioid analgesic. The code covers laboratory services used to confirm patient exposure, monitor therapeutic use, or evaluate potential misuse and is relevant to clinicians, laboratories, and payers managing opioid prescribing and monitoring at a national level. The code matters for public health and clinical oversight because tapentadol is an opioid with abuse potential and its detection can inform treatment, safety, and compliance decisions.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, expected sites of service, and the clinical context for ordering tapentadol testing. The publication outlines typical reimbursement and billing considerations, common modifiers used with laboratory services, and how this assay fits into broader toxicology and medication-monitoring workflows. It also highlights benchmarks and policy-relevant points where available and notes where input data are not provided. This summary is intended for a national audience of laboratory managers, billing staff, compliance officers, and clinicians involved in pain management and substance-use monitoring.
Billing Code Overview
CPT code 80372 describes a laboratory assay in which a lab analyst measures the amount of, or detects the presence of, tapentadol, a centrally acting opioid analgesic, in a patient specimen. This service is a clinical laboratory drug assay used to confirm exposure, monitor therapy, or investigate suspected misuse.
Service Type: Drug assay / toxicology testing
Typical Site of Service: Clinical laboratory or hospital laboratory testing facility
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with chronic neuropathic back pain treated with tapentadol presents for routine monitoring and for suspected nonadherence or possible diversion. The prescribing clinician orders a targeted urine or serum toxicology assay to detect and quantify tapentadol to confirm recent ingestion, assess therapeutic levels, or investigate unexpected clinical findings such as worsening pain, signs of sedation, or inconsistent pill counts. The specimen is collected at an outpatient laboratory or hospital clinical laboratory; the specimen is labeled and accompanied by the clinician's order. The laboratory performs a specific analytical assay for tapentadol — typically liquid chromatography with tandem mass spectrometry (LC-MS/MS) or an immunoassay followed by confirmatory testing — and reports qualitative or quantitative results to the ordering clinician. Results inform clinical decisions about ongoing opioid therapy, risk mitigation, or further toxicology evaluation. Typical sites of service are outpatient laboratories, hospital inpatient or outpatient laboratories, and emergency departments when acute overdose or toxicity is suspected.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional interpretation component of a laboratory test performed by a physician or qualified provider |